Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen McIlleron

Showing results (11-20 of 150) with videos related to

Pageof 15
Sort By:
Antimicrobial Agents and Chemotherapy|January 29, 2015
Reply to "breakpoints and drug exposure are inevitably closely linked"Tawanda Gumbo, Jotam G Pasipanodya, Peter Wash, et al.
European Journal of Clinical Pharmacology|June 17, 2010
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African childrenDoaa Elsherbiny, Yuan Ren, Helen McIlleron, et al.
The Journal of Antimicrobial Chemotherapy|January 17, 2020
Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIVIsmaeel Ebrahim, Gary Maartens, Lubbe Wiesner, et al.
BMC Medicine|December 4, 2013
Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art reviewStephen D Lawn, Graeme Meintjes, Helen McIlleron, et al.
The Journal of Infectious Diseases|May 27, 2015
Special populations and pharmacogenetic issues in tuberculosis drug development and clinical researchHelen McIlleron, Susan Abdel-Rahman, Joel Alex Dave, et al.
The Pediatric Infectious Disease Journal|March 19, 2011
Pyrazinamide plasma concentrations in young children with tuberculosisHelen McIlleron, Marianne Willemse, Hendrik Simon Schaaf, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2011
Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tabletsEric H Decloedt, Helen McIlleron, Peter Smith, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2006
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patientsHelen McIlleron, Peter Wash, André Burger, et al.
Journal of the International AIDS Society|June 10, 2014
Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settingsAlemseged Abdissa, Lubbe Wiesner, Helen McIlleron, et al.
Plos One|March 14, 2012
The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapyEric H Decloedt, Gary Maartens, Peter Smith, et al.
Pageof 15

Showing results (11-20 of 150) with videos related to

Sort By:
Pageof 15
Antimicrobial Agents and Chemotherapy|January 29, 2015
Reply to "breakpoints and drug exposure are inevitably closely linked"Tawanda Gumbo, Jotam G Pasipanodya, Peter Wash, et al.
European Journal of Clinical Pharmacology|June 17, 2010
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African childrenDoaa Elsherbiny, Yuan Ren, Helen McIlleron, et al.
The Journal of Antimicrobial Chemotherapy|January 17, 2020
Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIVIsmaeel Ebrahim, Gary Maartens, Lubbe Wiesner, et al.
BMC Medicine|December 4, 2013
Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art reviewStephen D Lawn, Graeme Meintjes, Helen McIlleron, et al.
The Journal of Infectious Diseases|May 27, 2015
Special populations and pharmacogenetic issues in tuberculosis drug development and clinical researchHelen McIlleron, Susan Abdel-Rahman, Joel Alex Dave, et al.
The Pediatric Infectious Disease Journal|March 19, 2011
Pyrazinamide plasma concentrations in young children with tuberculosisHelen McIlleron, Marianne Willemse, Hendrik Simon Schaaf, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2011
Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tabletsEric H Decloedt, Helen McIlleron, Peter Smith, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2006
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patientsHelen McIlleron, Peter Wash, André Burger, et al.
Journal of the International AIDS Society|June 10, 2014
Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settingsAlemseged Abdissa, Lubbe Wiesner, Helen McIlleron, et al.
Plos One|March 14, 2012
The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapyEric H Decloedt, Gary Maartens, Peter Smith, et al.
Pageof 15